Aharon Schwartz, PhD, Chairman
Dr. Aharon Schwartz retired after 36 years from Teva Pharmaceutical Industries where he served as Vice President Innovative Ventures. Previously at Teva, he also served as Vice President of the Copaxone Division, Vice President Business Development/Export Division and Head of the Pharmaceutical Division. Dr. Schwartz serves as Chairman of BioLineRx, BioCancell and Amorphical. He also serves as Director at Clal BIoTechnology, D-Pharm and MediWound. Dr. Schwartz received his Ph.D. in organic chemistry from the Weizmann Institute.
Ofer Gonen is the VP, for Business Development of the ARTE group and focuses on the day-to-day management of biomedical investments owned by a variety of investors like Teva, the Arison Group and the Abramson Group as well as other biotechnology, medical device and life sciences related holdings. Ofer Gonen serves as a vice president in Clal Biotechnology Industries, the largest life sciences investment fund in Israel. Under this capacity he acts as an executive board member of several portfolio companies (Gamida-Cell, Colbar, TransPharma, Polyheal, CureTech, MediWound). Prior thereto he was a technology consultant for various Israeli venture capital funds and served as the Academic Aide to the Governor of the Bank of Israel. Mr. Gonen has gained extensive experience in R&D and project management in defense oriented projects for which he was awarded the Israeli National Security Medal. Mr. Gonen holds M.Sc. degree in Computer Science, M.A. magna cum laude in Economics and Finance from Tel Aviv University and B.Sc. magna cum laude in Physics, Mathematics and Chemistry from the Hebrew University in Jerusalem, Israel.
For the past fifteen years, Mr. Goldberg has been actively involved with healthcare related companies ranging in stage from inception to commercialization. Mr. Goldberg is responsible for strategic investment decisions and technological development of CBI. Mr. Goldberg is also the managing director of Anatomy Medical Technology fund, CBI’s medical device investment arm.
Mr. Goldberg serves as an executive chairman and board member of several biotech and medical device companies, among them Biocancell (TASE: BICL), Curetech, Pi-Cardia, Cologuard, Biokine and SightDX. Mr. Goldberg holds an M.A. in Economics and Finance from Tel Aviv University and a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem.
Llew Keltner, MD, PhD
Llew Keltner, M.D., Ph.D., has a 30-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.
Dr. Keltner holds positions on the boards of Raptor Pharmaceuticals (NASDAQ:RPTP), Infostat, BioQuiddity, Oregon Life Sciences, and Goodwell Technologies. He is a previous Director of Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.
Steven R. Deitcher, MD
Steven R. Deitcher, MD, is co-founder, President, CEO and a Board Member of Medeor Therapeutics which started its activities in September 2014. Medeor is a clinical stage biotechnology start-up company focused on cellular therapy approaches to organ transplant immune tolerance and immuno-oncology.
Steven R. Deitcher, MD was Scientific Advisor to Verseon, a drug discovery biotechnology company between August 2013 and September 2015 and is has been serving in this capacity in Tosk Inc. since mid 2014. Prior to that, Dr. Dietcher was appointed President and Chief Executive Officer and a member of the Board of Directors for Talon Therapeutics (f/k/a Hana Biosciences), in August 2007 and served there till July 2013. Dr. Deitcher originally joined Talon as Executive Vice President of Development and Chief Medical Officer in May 2007. Since joining the company, Dr. Deitcher has transformed the organization into a focused, expert, and well-capitalized oncology drug development company. He is responsible for the rapid advancement (acceleration and amplification) of the Marqibo and Menadione Topical Lotion (TL) Programs, culminating in Marqibo accelerated approval in August 2012 and Menadione TL entry into Phase 2. Prior to joining Talon, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 25 years of experience in academic medicine as well as drug, device, and diagnostic test product discovery and development related to hematology, medical oncology, clinical thrombosis, and cardiovascular medicine.